Overview | Index | Clinical Trial Mechanisms | DAIDS Home

The AIDS Malignancy Consortium (AMC) is a collaborative network funded by the National Cancer Institute (NCI) to conduct clinical trials in subjects with AIDS malignancies, including non-Hodgkin's lymphoma, primary central nervous system lymphoma, Kaposi's sarcoma, and cervical cancer. The AMC often collaborates with the NIAID-sponsored Adult AIDS Clinical Trials Group, with the NCI-sponsored Clinical Trials Cooperative Groups, and with the AIDS Malignancy Bank.

AMC Research Agenda

The AMC was created to facilitate the rapid evaluation of hypothesis-driven early phase clinical trials that utilized the expertise of both NCI and NIAID-sponsored scientists. The following approaches are being investigated in trials: immune therapy directed against tumor-associated antigens; biologic therapy to alter the cytokine milieu; tumor differentiation therapy; anti-angiogenesis; and immune restoration. In addition to assessing potential anti-tumor activity and drug-drug interaction, the clinical trials evaluate the impact of therapy on viral load and underlying immune function. Plans are in progress to consider incorporation of other NIH-funded investigators to work on gynecological clinical research issues.

Examples of clinical studies:

• Pilot study of 5-azacytidine in HIV patients with relapsed and/or refractory Epstein-Barr virus-associated malignancies.
• Phase II trial of 9-cis retinoic acid (ALRT1057) in AIDS Kaposi's sarcoma (KS).
• CALGB 9550: Low dose IL-2 in AIDS lymphomas.
• Phase I trial to determine the safety, tolerance, and anti-tumor effects of ritonavir combined with interferon alpha-2b and stavudine in HIV-related KS.
• Pilot study of the effects of combination chemotherapy (modified-CHOP) and triple antiretroviral therapy on outcome and viral load in the treatment of AIDS related non-Hodgkin's lymphoma.
• Phase II study of 9-aminocamptothecin (9-AC/DMA) in patients with AIDS KS.
• A study of the effect of a single daily dose of RS-79070-194 (ganciclovir prodrug) on the incidence of KS in HIV positive subjects with detectable antibodies to KS herpesvirus.
• A randomized prephase II trial of interleukin-2, interleukin-12, or no additional therapy following response to ifosfamide/etoposide chemotherapy for refractory HIV associated non-Hodgkin's lymphoma.

For more information on AIDS oncology, please click here .

Accessing These Resources

Investigators wishing to have a therapy evaluated by the AMC should do the following:

1. Contact the AMC Operations Center (Dr. Jeannette Lee; e-mail: lee@lue.biosccc.uab.edu) or the NCI (Dr. Ellen Feigal; e-mail: ef30d@nih.gov) to determine whether the therapeutic concept might be of interest to the AMC. If collaborations are of interest:
2. AMC or NCI contacts will direct investigators on ways to interact with the group. This may involve submitting a concept proposal to the AMC Operations Center (Dr. Jeannette Lee) for review and forwarding to the AMC investigators.

AMC's interest or disinterest in further pursuing the proposed concept will be relayed to investigators and additional information may be requested.